Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced ...

Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...

The FDA responded with a complete response letter (CRL) to the resubmitted biologics license application (BLA) for RP1 (vusolimogene oderparepvec), an oncolytic virus therapy, in combination with ...

Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most ...

NeuroTherapia has concluded its Phase IIa clinical trial of NTRX-07, an orally available molecule, for Alzheimer's disease ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the 'Company”), a clinical-stage pharmaceutical company developing targeted ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...

Scientists have found markers of cognitive decline in a diet and gut microbiome-linked blood test that may help spot dementia ...

Italian climber Domenico Pozzovivo has announced he is returning from retirement and has signed with Solution Tech-Nippo-Rali ...

Trial Designed to Demonstrate Target Engagement, Safety, and Pharmacokinetics CLEVELAND, April 7, 2026 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company focused on developing oral ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will present new research at the American Association for Cancer Research (AACR) Annual Meeting, highlighting ...